Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial Evaluating Personalized Anal Squamous Cell Carcinoma Treatment Escalation Using Real-Time ctDNA Surveillance (PACER)

NCT07927998 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07927998 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial Evaluating Personalized Anal Squamous Cell Carcinoma Treatment Escalation Using Real-Time ctDNA Surveillance (PACER)
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
November 4, 2026
Completion date
November 4, 2029
Enrollment
25 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

anal cancer, anal carcinoma, anal squamous cell carcinoma

Arms

As registered; 1 arm.

  • Anal squamous cell carcinoma ExperimentalRetifanlimab

    Participants have pathologically confirmed anal squamous cell carcinoma

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Rate of ctDNA clearance at 12 weeks 12 weeks

    To determine the rate of ctDNA clearance at 12-weeks (pre-Cycle 4) in ASCC participants with MRD after completion of definitive-intent chemoradiation, following treatment with retifanlimab.

Patents and exclusivity

By drug, as the FDA Orange Book declares its patents.

  • Retifanlimab 1 Orange Book patentPatent cliff March 22, 2037 (USPTO PTE)
    • US 10577422; expires March 22, 2037; assignee Macrogenics Inc

Lead sponsor's other trials

Memorial Sloan Kettering Cancer Center, most recent start first.

Similar trials

Same condition (Anus Neoplasms) and phase, most recent start first.